# Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

> **NCT01714908** · PHASE2 · UNKNOWN · sponsor: **Jinming Yu** · enrollment: 100 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **OTHER:** Erlotinib w Concurrent Radiotherapy
- **OTHER:** etoposide/cis-platin (EP) w Concurrent Radiotherapy

## Key facts

- **NCT ID:** NCT01714908
- **Lead sponsor:** Jinming Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12-14
- **Primary completion:** 2018-08-20
- **Final completion:** 2018-10-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714908, "Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01714908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*